EPIRUS Biopharma (EPRS) Tops Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
EPIRUS Biopharmaceuticals (EPRS) PT Raised to $13 at Leerink Partners
March 25, 2015 6:19 AM EDTLeerink Partners analyst Jason Gerberry reiterated an Outperform rating and boosted his price target on EPIRUS Biopharmaceuticals (NASDAQ: EPRS) to $13.00 (from $10.00) saying the pipeline is on track and the company has a cash runway into 2016.
Gerberry commented, "This morning EPRS provided several... More
